The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Animal studies demonstrate reduced behavioral indicators of stress with DSIP administration
Diagnosed thyroid disorders are associated with depression and anxiety
HUNGER SUPPORT PATCH: Revolutionary GLP-1 Patches Technology To Manage Cravings
You may be at a higher risk of lower limb amputation if you have a history of amputation, have had blocked or narrowed blood vessels usually in your leg, or have had diabetic foot infection, ulcers, or sores
